In one embodiment, the invention comprises
the use of a composition comprising dimethylsulfoxide
(DMSO) in the preparation of a medication for the treatment
of stroke or brain injury, wherein said composition
additionally comprises one or more of the following: Larginine
and urea. About 1.0 to 8.0 grams of L-arginine
may be dissolved in a DMSO solution. DMSO may be
provided in a concentration of about 20% to about 40%.
In one embodiment, a dose of 70 grams of DMSO is used.
About 20% to about 60% urea can be used. In one embodiment,
a combination (e.g., a solution) of about 50%
DMSO and 50% urea is provided.
+
Together, DMSO and arginine may
have a combined, additive, or synergistic effect. In some
embodiments, DMSO and arginine (or NO) act on different
receptors or pathways to increase blood flow more
than either of the compounds administered alone. In other
embodiments, DMSO and arginine (or NO) act on the
same receptors or pathways to increase blood flow.
+
In other embodiments, DMS and L-arginine
are provided along with one or more of the following:
fructose 1,6-diphosphate, L-lysine, L-aspartate, urea,
DMSO, MSM, and other DMSO metabolites.
+Because arginine is the immediate precursor of
NO, urea, ornithine and agmatine, in some embodiments,
NO, urea, ornithine and agmatine are used in addition to
or instead of L-arginine in several of the compositions
described herein. Because arginine is synthesized from
citrulline, citrulline may be used in addition to or instead
of L-arginine in several of the compositions described
herein. Other forms of arginine, other than the L isomer
may also be used. The compositions described herein
may comprise nitric oxide synthase to facilitate the production
of NO from arginine.
+
As discussed above, L-arginine given as a continuous
intravenous infusion was able to reduce the levels
of endothelin-1, one of the most powerful vasoconstrictors
known and also lowered the serum levels of
asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of eNOS. L-arginine combined with L-aspartate
or L-lysine can increase its peak levels in physiological
conditions such as an increase in growth hormones and
bone metabolism. It is therefore anticipated that the addition
of L-lysine and /or L-aspartate to L-arginine should
increase the efficacy of this amino acid in traumatic or
degenerative brain conditions, according to several embodiments
of the invention.
+
In one embodiment, the present invention comprises
a composition comprising DMSO and L-arginine,
DMSO and urea, or DMSO, L-arginine, and urea. In other
embodiments, the present invention comprises a composition
comprising DMSO, L-arginine, and additional
compound selected from the group consisting of one or
more of the following: fructose 1,6-diphosphate, L-lysine,
L-aspartate, and urea. In one embodiment, a synergistic
effect is obtained when DSMO and L-arginine are combined
with these additional compounds.
+In another embodiment, the invention comprises
a DMSO solution and one or more of the following: Larginine,
fructose 1,6-diphosphate, L-lysine, L-aspartate,
and urea. In one embodiment, a synergistic effect
is obtained when DSMO is combined with these additional
compounds. In one embodiment, about 200 to 900
mg of L-lysine is dissolved in (or otherwise combined
with) the DMSO solution. In another embodiment, about
100 to 1,200 mg of the L-aspartate is dissolved in (or
otherwise combined with) the DMSO solution.
+
In one embodiment, the invention provides a
pharmaceutical formulation comprising DMSO, L-arginine,
and L-lysine. In one embodiment, the invention
comprises a pharmaceutical formulation comprising DMSO
and L-lysine. In another embodiment, one or more
additional amino acids are included.
